A Clinical Study Of Cytokine Induced Killer Cells For The Treatment Of Metastatic Renal Carcinoma

Background:Renal cell carcinoma is one of the most common cancers of the kidney. About20%～30%of patients with renal cell carcinoma have occurred diffusion and metastasis when they are diagnosed as renal cancer, however, effective treatments for metastatic renal cell carcinoma (MRCC) are lack currently. Sunitinib is a targeted drug known as the first-line therapy for metastatic renal cell carcinoma, however, the median PFS is only11months and adverse reactions rate is higher. Therefore, it is quite necessary to explore a new treatment for metastatic renal cell carcinoma. Nowadays, immunotherapy of metastatic renal cell carcinoma develops expeditiously, and the clinical research of cytokine-induced killer cells (CIK) has gained great progression. CIK cells are heterogeneous cell populations, which are from peripheral blood mononuclear cells co-cultured with IL-2, y-IFN, anti-CD3mAb in vitro. The study analyzed clinical data of MRCC from department of biotherapy of the affiliated tumor hospital of Zhengzhou University from May,2010to November,2011and all data were analyzed through statistical analysis.Objective:To investigate the clinical efficacy of cytokine induced killer cells (CIK) for metastatic renal cell carcinoma and provide new ideas for the treatment of metastatic renal cell carcinoma.Methods:In this retrospective analysis, we analyze21cases of MRCC, who received more than4cycles of CIK cells therapies. All the patients were from the department of biotherapy of the affiliated tumor hospital of Zhengzhou University. Our main observed standards were objective response rate(ORR), disease control rate (DCR) and time to progression (TTP), secondary observed standards were incidence of adverse reactions and the influencing factors for TTP, all data were analyzed through statistical analysis.Results:Of the21patients, there was0case which achieved PR,1PR,16SD, and4PD, ORR(CR+PR) accounted for4.76%(1/21), DCR(CR+PR+SD) accounted for80.95%(17/21), the overall median PFS was12.37months. For these patients, who had less metastasis or/and achieved more than6cycles of CIK cells therapy might have longer TTP, there was significant difference in statistics(P<0.01).Conclusion:The therapy of CIK cells for MRCC is safe and efficacy. At the same time, adverse events are low, patients with less metastasis or more cycles of CIK cell therapy may prolong TTP of patients with MRCC.